Access to medicines

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Retrieved on:

日曜日, 12月 17, 2023

TOKYO, Dec. 17, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel to treat one of the neglected tropical diseases, schistosomiasis, in preschool-aged children (3 months to 6 years of age) on December 15. EMA assessed arpraziquantel under the EU-Medicines for all (EU-M4all) *1 procedure for high-priority medicines intended for use in countries outside the European Union. For more details on arpraziquantel, please refer to the Consortium's press release.

Key Points:

EMA assessed arpraziquantel under the EU-Medicines for all (EU-M4all) *1 procedure for high-priority medicines intended for use in countries outside the European Union.
For more details on arpraziquantel, please refer to the Consortium's press release .
Astellas provided its innovative formulation technology to co-develop arpraziquantel as a member of the Consortium.
Initiatives in the Consortium apply to (3), and the positive CHMP scientific opinion by EMA of arpraziquantel represents a significant milestone in alignment with Astellas' Access to Health focus.

Patented Medicine Prices Review Board Risks Harming the Health of Canadians by Reducing Access to New Medicines

Retrieved on:

水曜日, 6月 23, 2021

Health sciences, Countries, Pharmaceutical sciences, Access to medicines, World Health Organization, Medication, Patented Medicine Prices Review Board, Canada, Pharmaceutical industry

IMC firmly maintains that industry is prepared to consult and collaborate with governments with a view to protecting the health of Canadians.

Key Points:

IMC firmly maintains that industry is prepared to consult and collaborate with governments with a view to protecting the health of Canadians.
Regulatory amendments to the Patented Medicine Prices Review Board (PMPRB), Canada's drug pricing ceiling regulator are set to be implemented on July 1.
These severe changes will impede R&D investment in Canada's biopharmaceutical sector and reduce access to new medicines for Canadians.
Our industry stands ready to collaborate with governments on changes to the PMPRB that will be less damaging to Canada's domestic life sciences capacity and timely access to medicines and vaccines for all Canadians.

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

Retrieved on:

水曜日, 4月 7, 2021

Articles, Ethics, World Health Organization, CAC 40, Sanofi, Pharmacy, Essential medicines, Corporate social responsibility, Access to medicines

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines

Key Points:

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion
Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the worlds poorest countries access to 30 essential medicines
PARIS April 7, 2021 In an open letter , Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy.
A cornerstone of Sanofis CSR strategy, Sanofi Global Health is a newly formed nonprofit unit within the company.
Leveraging the companys diverse and large portfolio of medicines and global footprint, Sanofi Global Health is dedicated to increasing access to medicines considered essential by the World Health Organization (WHO) for patients in 40 lower income countries.
Sanofi Global Health is the first global initiative to provide access to such a broad portfolio of medicines, in so many countries and across several therapeutic areas, while funding local support programs.

New Study Recognizes that Public Quality Standards Support US Generics Market

Retrieved on:

水曜日, 11月 13, 2019

Health, Articles, Pharmaceuticals policy, Pharmaceutical industry, Pharmacy, Access to medicines, World Health Organization, Prescription drug, Generic drug, Medication, United States Pharmacopeia, Association for Accessible Medicines

Researchers estimated these standards increased competition in the generic medicines market and reduced overall prescription drug costs by $11 billion in 2015 and 2016.

Key Points:

Researchers estimated these standards increased competition in the generic medicines market and reduced overall prescription drug costs by $11 billion in 2015 and 2016.
The Johns Hopkins study provides evidence in support of USP's Generics Access Plan , which launched in January to help increase access to medicines by facilitating generic competition through new and revised quality standards and related activities.
"We want to build on the collaborative process of public standards development to bring critical therapies to patients by ensuring a robust generic market."
Through our standards, advocacy and education, USP helps increase the availability of quality medicines, supplements and food for billions of people world-wide.

USP Announces Generics Access Plan

Retrieved on:

木曜日, 1月 31, 2019

Health, Articles, Pharmaceuticals policy, Life sciences, Pharmaceutical industry, Food and Drug Administration, United States Public Health Service, Generic drug, Access to medicines, United States Pharmacopeia

ROCKVILLE, Md., Jan. 31, 2019 /PRNewswire/ --USP today announced its Generics Access Plan, helping to increase access to medicines by facilitating generics competition through new and revised quality standards and related activities, including collaborations with the U.S. Food and Drug Administration (FDA) and others.

Key Points:

ROCKVILLE, Md., Jan. 31, 2019 /PRNewswire/ --USP today announced its Generics Access Plan, helping to increase access to medicines by facilitating generics competition through new and revised quality standards and related activities, including collaborations with the U.S. Food and Drug Administration (FDA) and others.
USP's new Generics Access Plan supports the FDA in its efforts to encourage development of new generic medicines to promote competition, help reduce drug prices and improve access to medicine for Americans.
"Manufacturers can rely on USP quality standards, helping accelerate availability of generic versions of off-patent medicines," said Piervincenzi.
USP's Generics Access Plan can help increase patient access to medicines by facilitating competition through new and revised standards, training and education, and collaborations with the FDA, industry representatives and others.